Comparison of anti-PR3 capture and anti-PR3 direct ELISA for detection of antineutrophil cytoplasmic antibodies (ANCA) in long-term clinical follow-up of PR3-ANCA-associated vasculitis patients.
A total of 118 sera from 11 patients with anti-neutrophil cytoplasmic antibodies against proteinase-3- (PR3-ANCA) associated vasculitis were retrospectively screened by anti-PR3 capture and anti-PR3 direct ELISA tests. We studied the relationship between capture and direct ELISA scores and the clinical activity of PR3-ANCA-associated vasculitis patients during follow-up. We also studied the ability of the anti-PR3 capture ELISA to detect positive values of PR3-ANCA in clinical vasculitis relapses. Only capture ELISA presented a significant relationship (p < 0.05) with clinical activity of PR3-ANCA-associated vasculitis patients over time. Capture ELISA appears to be a reliable method for detecting clinical relapses in this group of patients. Our results indicate that the new capture ELISA test is more effective than direct ELISA in the follow-up of patients with PR3-ANCA-associated vasculitis and in the detection of relapses.
Arranz
O
O
Nephrology Service, Hospital Clinic, Instituto de Investigaciones Biomédicas (IDIBAPS), Universidad de Barcelona, Spain. arranz@medicina.ub.es
Ara
J
J
Rodriguez
R
R
Quintó
L
L
Font
J
J
Mirapeix
E
E
Darnell
A
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood*; D001324:Autoantigens / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D053146:Myeloblastin; D012008:Recurrence; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D012697:Serine Endopeptidases / Q000097:blood*; D013997:Time Factors; D014657:Vasculitis / Q000097:blood*
D019268:Antibodies, Antineutrophil Cytoplasmic; D001324:Autoantigens; D012697:Serine Endopeptidases; D053146:Myeloblastin